Chronic thromboembolic pulmonary hypertension: a case-based discussion of current management and latest guidelines

Neha Sivaguru; Vaishnavi Sabesan; Patrick Kicker; Dan Schuller

doi:10.12746/swjm.v13i56.1487

Neha Sivaguru Texas Tech University Health Sciences Center El Paso
Vaishnavi Sabesan
Patrick Kicker
Dan Schuller

DOI: https://doi.org/10.12746/swjm.v13i56.1487

Abstract

Purpose of review: Frequently underdiagnosed, chronic thromboembolic pulmonary hypertension (CTEPH) is associated with high morbidity and mortality. We highlight recent advancements in evaluation and management.

Recent findings: This study focuses on a case-based management approach for CTEPH. It outlines the initial evaluation, treatment approach, and the importance of timely intervention. Although a surgical approach can potentially be curative, we discuss the role of medical management and balloon pulmonary angioplasty (BPA).

Summary: This review highlights the importance of early recognition, diagnostic evaluation, and current evidence-based multidisciplinary management of patients with CTEPH.

Keywords: Chronic thromboembolic pulmonary hypertension, pulmonary endarterectomy, balloon pulmonary angioplasty, riociguat.

Downloads

Download data is not yet available.

References

1.Papamatheakis DG, Poch DS, Fernandes TM, et al. Chronic thromboembolic pulmonary hypertension: JACC focus seminar. J Am Coll Cardiol. 2020;76(18):2225-2237. doi: 10.1016/j.jacc.2020.08.074.
2.Gall H, Hoeper MM, Richter MJ, et al. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe, and Japan. Eur Respir Rev. 2017;26(143):160121. doi: 10.1183/16000617.0121-2016.
3.Kicker P, Opina MT, Schuller D. Pulmonary Hypertension. In: Conn’s Current Therapy 2025. 1st ed. Elsevier; 2025:980-984.
4.Martin KA, Cuttica MJ. Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond. Hematology Am Soc Hematol Educ Program. 2021;2021(1):478-484. doi: 10.1182/hematology.2021000282.
5.Kim NH, D’Armini AM, Delcroix M, et al. Chronic thromboembolic pulmonary disease. Eur Respir J. 2024;64:2401294. doi: 10.1183/13993003.01294-2024.
6.Kovacs G, Dumitrescu D, Barner A, et al. Definition, clinical classification, and initial diagnosis of pulmonary hypertension: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:11-19. doi: 10.1016/j.ijcard.2018.08.083.
7.Hosokawa K, Watanabe H, Taniguchi Y, Ikeda N, Toru Inami, Yasuda S, et al. A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial. Circulation. 2023 Nov 13.
8.Inami T, Kataoka M, Shimura N, et al. Pressure-wire-guided percutaneous transluminal pulmonary angioplasty: a breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv. 2014;7(11):1297-1306. doi: 10.1016/j.jcin.2014.06.010.
9.Yanaka K, Nakayama K, Shinke T, et al. Sequential hybrid therapy with pulmonary endarterectomy and additional balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. J Am Heart Assoc. 2018;7(13):e008838. doi: 10.1161/JAHA.118.008838.
10.Ghofrani HA, Badr A, NG N. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):332-344. doi: 10.1056/NEJMoa1303342.
11.Simonneau G, D’Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: A long-term extension study (CHEST-2). Eur Respir J. 2015;45(5). doi: 10.1183/09031936.00087114.
12.Jaïs X, D’Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension. BENEFiT. J Am Coll Cardiol. 2008;52(25):2100-2109. doi: 10.1016/j.jacc.2008.08.059.
13.Ghofrani HA, Simonneau G, D’Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): Results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5(10):735-745. doi: 10.1016/s2213-2600(17)30305-3.
14.Andreassen AK, Ragnarsson A, Gude E, et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart. 2013;99(19):1415-1420.
15.Jaïs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): A multicentre, phase 3, open-label, randomised controlled trial. Lancet Respir Med. 2022;10(10):961-971.
16.Fedullo P, et al. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2011;183(12):1605-1613.
17.Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33(2):325-331.